What is the most rewarding aspect of your role?
Every day, we hear from patients with chronic mental health, addiction and pain issues who had very little hope of using conventional therapies. They tell us about the transformative effects of psychedelic medicine, and they are the reason we are helping to build our portfolio and expand the reach of psychedelic medicine. From ordinary people who have bravely suffered for many years in search of solutions, to the veterans, sports stars and celebrities who are passionate about the sector, the ultimate reward for us is helping more people overcome illnesses.
What's keeping you up at night?
“We live and breathe psychedelic medicine, and have been involved since the very earliest days.”
What makes your firm stand out?
We live and breathe psychedelic medicine, and have been involved since the very earliest days when there were only a handful of companies. Our first investments are now some of the biggest entities in the sector, and through our incubation work, we have learned first hand how to operate specialist psychedelic clinics, drug discovery, technology and media ventures from startup phase to public listing. The insights we have gained are invaluable as we continue to grow the fund.
What is one thing you would like investors to know about your firm?
Wesana is led by ex-professional ice hockey player Daniel Carcillo, who received a career-ending traumatic brain injury (TBI). After becoming an advocate for TBI sufferers and building a huge media presence, he was able to treat himself using psychedelic therapies. His company is now entering clinical trials of cutting edge drugs that use neuroplasticity and neurogenesis to heal physically damaged brain tissue. It is due to IPO later this year, and we have high hopes it will eventually be listed on the NASDAQ.
What are three things you look for when investing in a business?
What is the best piece of advice you've taken?
Who do you admire professionally?
About The Conscious Fund (TCF)
The Conscious Fund is the most active early-stage venture fund in the psychedelic medicine space. It invests into drug discovery, clinics, addiction programs, retreats, AI, telemedicine, media and training. Its global, platform-based approach helps to transform outcomes for patients with mental health, addiction and chronic pain issues.
To view more about this manager and their opportunities available,
People Behind the Product is an interview series produced by CoInvestor highlighting the key people behind the wide range of tax-efficient investment funds you can find on our platform. By showcasing the fund managers behind the product, we aim to provide greater insight to the expertise in the market and in doing so, help advisers and investors learn more about the tax-efficient sector.
If you are interested in participating in the series, or would like to find out more, get in touch with us at email@example.com